Anbogen Secures FDA Nod to Begin Phase I/II Trial of ABT-301 Triplet in Advanced Colorectal Cancer
Anbogen Therapeutics has received FDA clearance to initiate a Phase I/II clinical trial of ABT-301 in combination with tislelizumab and bevacizumab for patients with metastatic colorectal cancer (mCRC). The study will enroll 66 patients with pMMR or non-MSI-H tumors—types known for poor response to immunotherapies—across sites in Taiwan and Australia.
“We are excited to advance ABT-301 into the clinic for patients with hard-to-treat mCRC,” said a spokesperson from Anbogen. “The FDA’s clearance highlights the strength of our preclinical and early clinical data, as ...
